Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Paclitaxel + Pertuzumab + Trastuzumab
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Paclitaxel Taxol 7-Epipaclitaxel Antimicrotubule Agent 13 BCL2 Family Inhibitor 6 Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).
Pertuzumab Perjeta 2C4 Antibody HER2 (ERBB2) Antibody 53 Perjeta (pertuzumab) is a monoclonal antibody that binds ERBB2 (HER2) to prevent dimerization and subsequent HER signaling, thereby resulting in apoptosis and tumor growth inhibition (PMID: 15699478). Perjeta (pertuzumab) is FDA approved in combination with Herceptin (trastuzumab) and Taxotere (docetaxel) for patients with ERBB2 (HER2)-positive breast cancer and in combination with Herceptin (trastuzumab) and chemotherapy as neoadjuvant treatment for patients with ERBB2 (HER2)-positive breast cancer (FDA.gov).
Trastuzumab Herceptin Anti HER2 HER2 (ERBB2) Antibody 53 Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04301375 Phase II Paclitaxel + Pertuzumab + Trastuzumab Ado-trastuzumab emtansine Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial) (ELPIS) Not yet recruiting 1
NCT03498521 Phase II Atezolizumab + Paclitaxel Carboplatin Carboplatin + Paclitaxel Olaparib Vismodegib Alectinib Bevacizumab + Erlotinib Cisplatin + Gemcitabine Cobimetinib + Vemurafenib Ipatasertib + Paclitaxel Cisplatin + Paclitaxel Gemcitabine Atezolizumab Entrectinib Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Ipatasertib Carboplatin + Gemcitabine A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO) Recruiting 35
NCT04784715 Phase III Pertuzumab + Trastuzumab deruxtecan Docetaxel + Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Trastuzumab deruxtecan Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) Recruiting USA | CAN 27
NCT02344472 Phase III Fulvestrant + Pertuzumab + Ribociclib + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Docetaxel + Pertuzumab + Trastuzumab Capecitabine + Pertuzumab + Trastuzumab Exemestane + Pertuzumab + Ribociclib + Trastuzumab Letrozole + Pertuzumab + Ribociclib + Trastuzumab Eribulin + Pertuzumab + Trastuzumab Anastrozole + Pertuzumab + Ribociclib + Trastuzumab Goserelin + Pertuzumab + Ribociclib + Trastuzumab Pertuzumab + Trastuzumab + Vinorelbine Nab-paclitaxel + Pertuzumab + Trastuzumab Leuprolide + Pertuzumab + Ribociclib + Trastuzumab Detect V / CHEVENDO (Chemo vs. Endo) Recruiting 1
NCT01855828 Phase II Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Epirubicin + Fluorouracil + Pertuzumab + Trastuzumab Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer Completed USA 0
NCT04266249 Phase II Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Ado-trastuzumab emtansine Docetaxel + Pertuzumab + Trastuzumab Nab-paclitaxel + Pertuzumab + Trastuzumab CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy Recruiting USA 1
NCT03716180 Phase I Paclitaxel + Pertuzumab + Trastuzumab DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC Active, not recruiting USA 0
NCT01276041 Phase II Paclitaxel + Pertuzumab + Trastuzumab Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer Completed USA 0
NCT03726879 Phase III Cyclophosphamide + Doxorubicin Atezolizumab + Cyclophosphamide + Doxorubicin Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050) Active, not recruiting USA | CAN 11
NCT03644186 Phase II Letrozole + Palbociclib + Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (TOUCH) Recruiting 4
NCT01730833 Phase II Paclitaxel + Pertuzumab + Trastuzumab Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer Active, not recruiting USA 0
NCT03747120 Phase II Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab Paclitaxel + Pembrolizumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab Recruiting USA 0
NCT03412643 Phase II Cyclophosphamide + Doxorubicin Paclitaxel + Pertuzumab + Trastuzumab Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling (FB-12) Recruiting USA 0
NCT04425018 Phase II Paclitaxel + Pertuzumab + Trastuzumab Margetuximab-cmkb + Paclitaxel + Pertuzumab MARGetuximab Or Trastuzumab (MARGOT) (MARGOT) Recruiting USA 0
NCT03199885 Phase III Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer Recruiting USA | CAN 0
NCT01847001 Phase II Propranolol Paclitaxel + Pertuzumab + Trastuzumab Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy Completed USA 0


Additional content available in CKB BOOST